{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:46:59Z","timestamp":1793191619198,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40801-022-00305-7","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:05:54Z","timestamp":1654779954000},"page":"451-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Long-Term Treatment with Stiripentol in Children and Adults with Drug-Resistant Epilepsies: A Retrospective Cohort Study of 196 Patients"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-1969","authenticated-orcid":false,"given":"Simona","family":"Balestrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5166-8401","authenticated-orcid":false,"given":"Viola","family":"Doccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-5781","authenticated-orcid":false,"given":"Alessandra","family":"Boncristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-621X","authenticated-orcid":false,"given":"Matteo","family":"Lenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5889-9280","authenticated-orcid":false,"given":"Salvatore","family":"De Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7272-7079","authenticated-orcid":false,"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"305_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","volume":"4","author":"C Chiron","year":"2007","unstructured":"Chiron C. Stiripentol. Neurotherapeutics. 2007;4:123\u20135.","journal-title":"Neurotherapeutics"},{"key":"305_CR2","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.aaa1299","volume":"347","author":"N Sada","year":"2015","unstructured":"Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347:1362\u20137.","journal-title":"Science"},{"key":"305_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jnr.23688","volume":"94","author":"M Verleye","year":"2016","unstructured":"Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels: neuroprotective effect of stiripentol. J Neurosci Res. 2016;94:179\u201389.","journal-title":"J Neurosci Res"},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, d\u2019Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group. Lancet. 2000;356:1638\u201342.","journal-title":"Lancet"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1528-1157.2002.13802.x","volume":"43","author":"R Guerrini","year":"2002","unstructured":"Guerrini R, Tonnelier S, d\u2019Athis P, Rey E, Vincent J, Pons G. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia. 2002;43:155.","journal-title":"Epilepsia"},{"issue":"Suppl. 3","key":"305_CR6","first-page":"S39","volume":"60","author":"JH Cross","year":"2019","unstructured":"Cross JH, Caraballo RH, Nabbout R, Vigevano F, Guerrini R, Lagae L. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia. 2019;60(Suppl. 3):S39-48.","journal-title":"Epilepsia"},{"key":"305_CR7","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s40265-019-01204-y","volume":"79","author":"JE Frampton","year":"2019","unstructured":"Frampton JE. Stiripentol: a review in Dravet syndrome. Drugs. 2019;79:1785\u201396.","journal-title":"Drugs"},{"key":"305_CR8","doi-asserted-by":"crossref","unstructured":"Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54:1595\u2013604.","DOI":"10.1111\/epi.12303"},{"key":"305_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ane.12611","volume":"135","author":"S Balestrini","year":"2017","unstructured":"Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135:73\u20139.","journal-title":"Acta Neurol Scand"},{"key":"305_CR10","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/epi.14536","volume":"59","author":"C Chiron","year":"2018","unstructured":"Chiron C, Helias M, Kaminska A, Laroche C, de Toffol B, Dulac O, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59:1705\u201317.","journal-title":"Epilepsia"},{"key":"305_CR11","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1111\/epi.16684","volume":"61","author":"Q Zulfiqar Ali","year":"2020","unstructured":"Zulfiqar Ali Q, Marques P, Selvarajah A, Tabarestani S, Sadoway T, Andrade DM. Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine. Epilepsia. 2020;61:2435\u201341.","journal-title":"Epilepsia"},{"key":"305_CR12","unstructured":"Diacomit: summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/10300\/smpc. Accessed 10 May 2022."},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/epi.16363","volume":"60","author":"A Rosati","year":"2019","unstructured":"Rosati A, Boncristiano A, Doccini V, Pugi A, Pisano T, Lenge M, et al. Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: a single center prospective observational study. Epilepsia. 2019;60:2255\u201362.","journal-title":"Epilepsia"},{"key":"305_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512\u201321.","journal-title":"Epilepsia"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","volume":"113","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Ohtsuka Y. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90\u20137.","journal-title":"Epilepsy Res"},{"key":"305_CR16","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","volume":"40","author":"J Perez","year":"1999","unstructured":"Perez J, Chiron C, Musial C, Rey E, Blehaut H, d\u2019Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618\u201326.","journal-title":"Epilepsia"},{"key":"305_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/dmcn.13704","volume":"60","author":"KA Myers","year":"2018","unstructured":"Myers KA, Lightfoot P, Patil SG, Cross JH, Scheffer IE. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60:574\u20138.","journal-title":"Dev Med Child Neurol"},{"key":"305_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3988\/jcn.2018.14.1.22","volume":"14","author":"MJ Cho","year":"2018","unstructured":"Cho MJ, Kwon SS, Ko A, Lee S-T, Lee YM, Kim HD, et al. Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations. J Clin Neurol. 2018;14:22.","journal-title":"J Clin Neurol"},{"key":"305_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106535","volume":"170","author":"M Yamada","year":"2021","unstructured":"Yamada M, Suzuki K, Matsui D, Inoue Y, Ohtsuka Y. Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: interim report of a post-marketing surveillance study in Japan. Epilepsy Res. 2021;170: 106535.","journal-title":"Epilepsy Res"},{"key":"305_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0883073818811538","volume":"34","author":"EP Y\u0131ld\u0131z","year":"2019","unstructured":"Y\u0131ld\u0131z EP, Ozkan MU, Uzunhan TA, Bekta\u015f G, Tatl\u0131 B, Ayd\u0131nl\u0131 N, et al. Efficacy of stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol. 2019;34:33\u20137.","journal-title":"J Child Neurol"},{"key":"305_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/08830738060210062101","volume":"21","author":"C Chiron","year":"2006","unstructured":"Chiron C, Tonnelier S, Rey E, Brunet M-L, Tran A, d\u2019Athis P, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol. 2006;21:496\u2013502.","journal-title":"J Child Neurol"},{"key":"305_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.seizure.2021.03.019","volume":"88","author":"L Habermehl","year":"2021","unstructured":"Habermehl L, Mross PM, Krause K, Immisch I, Chiru D, Zahnert F, et al. Stiripentol in the treatment of adults with focal epilepsy: a retrospective analysis. Seizure. 2021;88:7\u201311.","journal-title":"Seizure."},{"key":"305_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1528-1157.1993.tb02416.x","volume":"34","author":"JR Farwell","year":"1993","unstructured":"Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993;34:305\u201311.","journal-title":"Epilepsia"},{"key":"305_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","volume":"47","author":"PP Quilichini","year":"2006","unstructured":"Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia. 2006;47:704\u201316.","journal-title":"Epilepsia"},{"key":"305_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eplepsyres.2019.04.006","volume":"154","author":"TA Warner","year":"2019","unstructured":"Warner TA, Smith NK, Kang J-Q. The therapeutic effect of stiripentol in Gabrg2 mice associated with epileptic encephalopathy. Epilepsy Res. 2019;154:8\u201312.","journal-title":"Epilepsy Res"},{"key":"305_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40263-017-0432-1","volume":"31","author":"KC Nickels","year":"2017","unstructured":"Nickels KC, Wirrell EC. Stiripentol in the management of epilepsy. CNS Drugs. 2017;31:405\u201316.","journal-title":"CNS Drugs"},{"issue":"5","key":"305_CR27","first-page":"CD009887","volume":"5","author":"F Brigo","year":"2020","unstructured":"Brigo F, Igwe SC, Bragazzi NL. Stiripentol add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2020;5(5):CD009887.","journal-title":"Cochrane Database Syst Rev"},{"key":"305_CR28","doi-asserted-by":"publisher","unstructured":"Silvennoinen K, Martins Custodio H, Balestrini S, Rugg-Gunn F, England Research Consortium G, Sisodiya SM. Complex epilepsy: it\u2019s all in the history. Pract Neurol. 2020. https:\/\/doi.org\/10.1136\/practneurol-2020-002522","DOI":"10.1136\/practneurol-2020-002522"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00305-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00305-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00305-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:17:59Z","timestamp":1660954679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00305-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00305-7","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"26 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Renzo Guerrini has acted as an investigator for studies with Zogenix, Biocodex, UCB, Angelini and Eisai Inc. He has been a speaker and on advisory boards for Zogenix, Biocodex, Novartis, Biomarin and GW Pharma, outside the submitted work. Simona Balestrini reports personal fees from Biocodex, Eisai and UCB Pharma, outside the submitted work. Viola Doccini received a travel grant from Biocodex, partly related to the submitted work. Alessandra Boncristiano, Matteo Lenge and Salvatore De Masi, do not have any relevant competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Approval was obtained from the Paediatric Ethics Committee of the Tuscany Region. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study or their parents or legal guardians, as appropriate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}